INTRODUCTION
Haemangiosarcoma (HSA) is a malignant neoplasm that develops within highly vascular structures such as the spleen, heart and liver (Pounden & Sprunger 1947 , Brown et al . 1985 , Ward et al . 1994 , Smith 2003 , Liptak et al . 2004 , Boston et al . 2011 , Eberle et al . 2012 . These neoplasms are common in dogs, representing 12% to 21% of all mesenchymal malignancies, with an estimated incidence rate of 24/100,000 dogs per year (Brown et al . 1985 , Smith 2003 , Gamlem & Nordstoga 2008 , Eberle et al . 2012 . Despite resection of the primary neoplasm, survival times (STs) are poor, with most dogs dying due to progressive metastatic disease within 2 -3 months (Brown et al . 1985 , Wood et al . 1998 , Clifford et al . 2000 , Dahl et al . 2008 , Wendelburg et al . 2015 . Conventional chemotherapy using cytotoxic drugs or other adjuvants (Hammer et al . 1991 ) is associated with some improvement in outcome, but STs remain poor, with reported median survival times (MSTs) of 91 to 273 days (Brown et al . 1985 , Johnson et al . 1989 , Vail et al . 1995 , Sorenmo et al . 2004 , Dervisis et al . 2011 , Kahn et al . 2013 , Finotello et al . 2015 , Gardner et al . 2015 . Identification of additional or alternative therapeutic modalities that will prolong ST in dogs with HSA is clearly needed.
HSA was previously presumed to arise from vascular endothelial cells, but recent evidence suggests that a pleuripotential bone marrow progenitor cell is the more likely origin (Tamburini et al . 2010 , Kim et al . 2015b ). The tumour has been shown to strongly express angiogenic molecules such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and tumour necrosis factor-alpha (TNF-α ) (Balasubramanian & Evens 2006 , Yonemaru et al . 2006 , Asa et al . 2012 , Farhang Ghahremani et al . 2014 , Frenz et al . 2014 , Fukumoto et al . 2015 , Adachi et al . 2016 , making angiogenesis a potential (Gardner et al . 2015 ) . VEGF concentration is elevated in plasma, serum and effusions in HSA cases (Clifford et al . 2001 , Clifford et al . 2002 , Yonemaru et al . 2006 , Frenz et al . 2014 . However, there is increasing evidence that progression of the disease requires coordination between the tumour and its microenvironment, with pro-angiogenic, immunomodulatory and pro-inflammatory pathways all playing important roles (Tamburini et al . 2010 , Kim et al . 2015b ).
Thalidomide was developed as a sedative in 1957 and was also demonstrated to have some anti-nausea properties (Franks et al . 2004 , Vargesson 2015 . The drug was responsible for significant birth defects during the 1960s when used by women during pregnancy to manage morning sickness, and it was withdrawn from sale in 1961 (Vargesson 2015 ) . Thalidomide is now known to influence the expression of several angiogenesis genes, including VEGF, fibroblast growth factor ( β -FGF) and hepatocyte growth factor (HGF). Thalidomide also has an immunomodulatory effect, demonstrating the inhibition of TNF-α ; interleukins (IL) 1 β , 6 and 12; and granulocyte macrophage colony-stimulating factor (GM-CSF). Thalidomide is also thought to have a proinflammatory role, stimulating the anticancer activity of T cells by inducing increased lymphocyte proliferation, cytokine production and cytotoxic activity (Kim et al . 2015a ).
There have been previous reports of thalidomide being used for the treatment of canine HSA, and prolonged survival was observed in some patients (Clifford et al . 2000 , Woods et al . 2004 , Finotello et al . 2016 ). Compared to many other chemotherapeutic drugs, thalidomide has the advantages of being well tolerated by dogs and can be orally administered at home. In toxicity trials, no neurological, haematological, biochemical or endocrine disease was noted after prolonged administration to 56 beagles at doses of up to 1000 mg/kg/day (Teo et al . 2001 ) . In a more recent clinical study, somnolence lasting for a few hours after thalidomide administration was reported in up to 15% of dogs, but no other significant toxicities or haematological changes were observed at doses of both 10 mg/kg/day and 20/ mg/kg/day (de Campos et al . 2016 ) .
The aim of this study was to assess the STs of dogs with splenic HSA that received thalidomide. STs were compared to historical controls. To our knowledge, this is the largest investigation of thalidomide for the treatment of HSA.
MATERIALS AND METHODS

Thalidomide preparation
Thalidomide was prepared at Massey University using a twostep process as previously described (Muller et al . 1999 ) . Briefly, glutamine was reacted with N-carbethoxyphthalimide in water in the presence of sodium carbonate (99% Riedel de Hahn, water free) at room temperature. Then, the product of this reaction (N-phthaloyl-L-glutamine) was reacted at reflux with 1,1 ′ -carbonyldiimidazole in the presence of a catalytic amount of N,N-dimethylaminopyridine in tetrahydrofuran. The two procedures were followed exactly as described (Muller et al . 1999 ) , with the only alterations being that the first step was based on 100 g of N-carbethoxyphthalimide, and the second step was based on 100 g of carbonyldiimidazole. All yields and analytical data were as previously reported (Muller et al . 1999 ) . Confirmation of 99·7% synthesis purity was conducted by nuclear magnetic resonance (600 MHz) analysis.
Clients were asked to read and sign a consent form indicating they understood the potential human health implications of thalidomide exposure, and women of child-bearing age were advised not to handle the drug. Non-sterile latex gloves were supplied to the owners to be worn at the time of drug administration, with recommendations for hands to be washed after handling. Each client was provided with a lockable box for storage of the thalidomide to help restrict access to the drug by other persons.
Clients were provided with 30 days' supply of the drug at a time. Thalidomide was dispensed into individual gel capsules at a previously recommended dose of 8·7 mg/kg once daily (Woods et al . 2004 ) . Each 30-day batch of capsules was prepared from the bulk supply of thalidomide, which was cool-stored in a sealed container (Sigma-Aldrich 2017). Capsules were individually weighed during preparation, with a 10% tolerance for the actual dispensed weight of capsule compared to the desired dose.
Patient inclusion
Inclusion criteria for dogs recruited to the study included recovery after splenectomy and a histological diagnosis of HSA. There were no exclusion criteria. Sections from all tumours were confirmed to be splenic HSA with histology and immunohistochemistry (Factor VIII-related antigen and/or CD31). The patient signalment, bodyweight and the date of surgery were recorded. Complete haematological and biochemical evaluations were also performed if these had not been performed at the time of splenectomy. As a minimum, packed cell volume and total solids were measured in all dogs.
Tumour staging was performed in all dogs included in the study before commencing thalidomide (Table 1 ) . This was achieved with CT imaging of the abdomen and thorax using 1·5 mm slices (Jones et al . 2016 ). All dogs were sedated for the scan with 0·005 mg/kg medotomidine and 0·1 mg/kg torbugesic, administrated intravenously. The presence and location of any hypoattenuated (liver/heart) or hyperattenuated (lung) lesions were noted, but fine needle aspiration or biopsies were not performed. A contrast agent was not utilised. Sedation was reversed using 0·001 mg/kg atipamazole (subcutaneously). After recovery from sedation, the dogs were discharged to their owners. Treatment with thalidomide was commenced that evening. Because sedation has been reported as a consistent side effect of thalidomide treatment (Woods et al . 2004 , de Campos et al . 2016 , owners were encouraged to give the medication to their dog in 
Follow-up examination
Owners were required to contact the principle investigator (JB) every month in order to receive further thalidomide medication for their dogs. On each occasion, the owners provided information on their dog's current status, including activity levels and any side effects. All animals that remained alive 3 months after commencing the study were re-presented for a full physical examination by the principal investigator. Staging evaluation of the abdomen and thorax was performed using a CT scan, using the protocol as outlined above.
In the event of the dog's death or euthanasia, the primary care veterinarian was asked to confirm the cause of death. A cosmetic post mortem examination of both thoracic and abdominal cavities was performed by the primary care veterinarian with the purpose of obtaining samples of any secondary lesions, which were collected for histopathology if they were present. Any unused medication was returned to the primary investigator for disposal.
Statistical analysis
Analyses were performed with statistical software (SPSS v24·0·0; IBM). Death or euthanasia due to the HSA was the primary end point for the study. STs were calculated from the date of surgery until the date of death. For survival calculations, dogs that died because of their tumour were considered completed events. Dogs that were still alive at the time of the study were censored at the close of the study.
ST was calculated from the date of splenectomy (T0) to death or censor date. The interval between when splenectomy was performed and the start of thalidomide therapy was defined as the treatment gap.
The Kaplan-Meier method was used to analyse ST according to age, gender, neuter status and tumour stage. Cox regression analysis was performed to assess the impact of the treatment group on outcomes. P<0·05 was considered significant.
The study was approved by the Massey University Animal Ethics Committee (reference MU 11/56).
RESULTS
Patient characteristics
Patient and tumour characteristics are summarised in Table 2 . From August 2012 to December 2014, 15 dogs were recruited. The age of the dogs ranged from 7 to 14 years (median 10 years). Eight were male (five neutered), and seven were female (six spayed). No significant abnormalities were evident on haematology and biochemical analysis in any dog.
Tumour staging
Five dogs had stage 3 disease based on the recognition of hypoattenuated lesions within the liver on CT scan images (Jones et al . 2016 ) . No concurrent thoracic or cardiac lesions were identified in any dog. The suspected metastatic lesions ranged in size from isolated clusters of 4 mm hypoattenuated masses to a large 4 cm multi-lobulated hypoattenuated mass within the left lateral lobe. A fifth dog had stage 3 disease associated with a histological diagnosis of metastatic lesions within the omentum. In the remaining 10 dogs, no evidence of metastatic lesions was identified in any abdominal or thoracic organ (stage 2).
Patient outcomes
The follow-up period ranged from 31 to 744 days (median 90 days). All results are summarised in Table 2 .
All but one dog enrolled in the study died during the study period. A diagnosis of haemoabdomen due to bleeding from one or multiple metastatic lesions in the abdomen was confirmed at post mortem examination in 12 dogs. In another dog, extensive bleeding restricted to the retroperitoneal region was identified at post mortem examination, with histological evidence of HSA in the adjacent kidney. One dog was euthanased 628 days after surgery due to progressive senile behaviour and separation anxiety. No evidence of neoplasm recurrence was observed on CT scan of the chest and abdomen, which was performed 1 day before euthanasia; a post mortem examination was not performed. One dog remained alive at the end of study period, 594 days after surgery.
Medication compliance and side effects
To the best of our knowledge, all dogs received their daily dose of thalidomide continuously until their death once treatment was started, with no disruption or adjustment in the dose or dosing interval due to side effects or logistical problems with delivery of medications.
All owners commented on some sedation within 30 minutes after drug administration, but in no dog was this of sufficient concern to warrant a change in the administered dose. One dog, the lightest in the study at 6·5 kg, was reportedly mildly stuporous for the first few days after medication commenced, but these effects resolved by the end of the first week with no change in treatment dose. One police dog and one guide dog remained fully working while on thalidomide, with no reported change in their concentration or working routines.
No other side effects were reported while dogs were receiving thalidomide medication. (Fig 1 ) ( Table 3 ) . A statistical analysis of this difference was not reported due to the small number of cases in each group.
Survival times -effect of treatment delay
The median time to start thalidomide treatment was 11 days after surgery due to the delay in obtaining histological confirmation and subsequent examination for staging. Two dogs did not start treatment until more than 30 days after surgery, and one dog did not start until 62 days after surgery. There was no apparent influence of this treatment delay on outcomes (Hazard Ratio 1·010, 95% CI 0·97 to 1·049, P=0·59), but this result may reflect a type II error.
DISCUSSION
The present study suggests that thalidomide treatment may improve STs for patients with splenic HSA because previous reports indicate much shorter STs for dogs with this disease (see Table 3 ). Previous studies had suggested that a good patient response was possible with this drug, but these clinical trials were stopped due to the rising cost and restricted availability of thalidomide (Woods et al . 2004 ) . The results of the present study support the potential of thalidomide as a useful adjuvant therapy for canine splenic HSA. The effects of thalidomide appeared to be most profound in dogs that did not have evidence of distant metastases at the time of commencing treatment (stage 2). While this observation requires confirmation and the reason requires further investigation, the apparent influence of stage on patient outcomes suggests that the angiogenic switch could become self-sustaining beyond a certain point in tumourigenesis, and a drug such as thalidomide can no longer disrupt progression of a macroscopic lesion.
The prognosis for dogs with splenic HSA is generally considered poor (Thamm 2013 ) . While surgery is the gold-standard therapy for HSA (Bergman 2012 ) , it is largely palliative as micrometastasis has usually occurred at the time of surgery (Clifford et al . 2000 ) . Chemotherapeutic protocols using doxorubicin, doxorubicin with cyclophosphamide, vincristine with cyclophosphamide and doxorubicin, dacarbazine and vincristine have all been used (Vail et al . 1995 , Sorenmo et al . 2004 , Kim et al . 2007 , Dervisis et al . 2011 , Kahn et al . 2013 , Finotello et al . 2015 . While adjuvant chemotherapy will increase the ST over surgery alone, the duration of remission remains short, with most protocols reporting MSTs of between 91 and 273 days (Table 3 ) .
HSA has been shown to express a variety of pro-angiogenic cytokines, including VEGF and PDGF (Farhang Ghahremani et al . 2014 , Frenz et al . 2014 , Fukumoto et al . 2015 , Adachi et al . 2016 . However, the use of small molecule inhibitor therapy against these cytokines ( i.e. toceranib phosphate) did not show an improvement in disease-free interval or overall survival (Gardner et al . 2015 ) . The lack of apparent response to toceranib may have been due to its delayed administration, which was not started until full-course doxorubicin chemotherapy was completed.
It is equally possible that targeting of angiogenesis alone is insufficient to stem the relentless progression of a tumour (Jain 2001 , Beil 2017 ; in other tumour types, anti-angiogenic treatment has often failed to meet expectations, leading to a rethinking of the role for this strategy (Aalders et al . 2017 ) . The increased expression of hypoxia-inducible genes like VEGF and hypoxiainducible factor (HIF-1) should not be surprising as most solid tumours will become hypoxic during growth. Newer theories suggest that clonal evolution within the tumour may favour cells that are able to exploit a synergy between the up-regulation of hypoxia response genes and pro-inflammatory genes to create a microenvironment sympathetic for growth and survival (Tamburini et al . 2010 ) . In canine HSA, several pro-inflammatory gene pathways are up-regulated, including interleukin-8 (IL-8), stromal cell-derived factor-1α (SDF1α, also known as CXCL12) and its receptor (CXCR4) and modified sphingosines (S1P) (Oliveira et al . 2009 , Asa et al . 2012 , Adachi et al . 2016 . These activities occur alongside increases in pro-angiogenic signals, including VEGF, bFGF and TNF-α (Tamburini et al . 2010 ) .
Thalidomide has a variety of properties that make it a compelling drug choice for the treatment of HSA (Adlard 2000 , Eisen 2002 , Franks et al . 2004 , Woods et al . 2004 , Vacca et al . 2005 , Balasubramanian & Evens 2006 , Ganjoo & Jacobs 2010 , with an ability to target not only angiogenesis but also the immunomodulatory and pro-inflammatory components considered important for establishment and progression of metastatic nodules (Tamburini et al . 2010 ) . The drug induces down-regulation of SDF1α and its receptor (CXCR4) as well as NF-κ B (Oliveira et al . 2009 ). As mentioned above, these cytokines are known to influence the expression of several angiogenesis genes, including VEGF, β -FGF and HGF. It also co-stimulates primary human T lymphocytes to increase their anticancer activity.
The thalidomide legacy is profound because of the large number of teratogenic deformities that occurred due to its inappropriate licensing for use in pregnant women (Franks et al . 2004 , Vargesson 2015 . In humans, prescription is now only possible by compliance with STEPS (System for Thalidomide Education and Prescribing Safety), and access to the drug is tightly regulated in almost all countries in the world. This is unfortunate because, based on the results of this study, thalidomide may prove to be an important drug in the management of canine HSA and its human equivalent, angiosarcoma (Raina et al . 2007 ). There are also close similarities in the gene expression profiles of HSA and human angiosarcoma (Tamburini et al . 2010 ) . The canine disease may prove to be a useful model to investigate the influence of the microenvironment on tumour progression and the role for thalidomide and its derivatives in influencing oncogenesis.
Monitoring for haematological or biochemical toxicities was not performed as part of this study. Apart from drowsiness and the well-known teratogenic effects, chronic use of thalidomide tends to be well tolerated (Prommer 2010 ) . Human patients have experienced peripheral neurological disturbances such as hypoand hyperalgesia, impaired temperature sensitivity and polyneuritis (Teo et al . 2001 ) . Other less commonly reported side effects include constipation, deep vein thrombosis and a mild skin rash (Prommer 2010 ) . In previous studies, no evidence for systemic toxicity in dogs was reported with thalidomide doses ranging from 10 to 1000 mg/kg/day (Teo et al . 2001 , de Campos et al . 2016 .
The optimal therapeutic dose of thalidomide has not been well established in the dog. Aside from a specific toxicity study, where doses ranging from 43 to 1000 mg/kg/day were used, various clinical reports have used doses ranging from 2 to 3 mg/kg every 24 or 48 hours ( (Finotello et al . 2016 ) to 20 mg/kg/day (de Campos et al . 2016 ) . The dose used in the study was based on recommendations from the authors of the discontinued trial of thalidomide in canine HSA, in which some beneficial effects had been noted (Woods et al . 2004 ) . Further studies may be required to help determine the optimal therapeutic dose in the dog.
In this study, thalidomide did not prevent the development of metastatic disease, with almost all dogs eventually developing haemoabdomen due to a ruptured secondary tumour. However, dogs with microscopic metastatic disease (stage 2) appeared to respond better than dogs with grossly visible metastatic disease (stage 3), suggesting that the influence of thalidomide is best achieved when metastases are small and effects on the tumour microenvironment may be more profound. Combining thalidomide with conventional cytotoxic drugs may be of value, particularly given the similarities in ST achieved in this study. Continuous low-dose chemotherapy is purported to exert its effect via immunomodulatory and anti-angiogenic pathways (Lana et al . 2007 , Mutsaers 2009 , and a synergism of anti-tumour activity has previously been shown with thalidomide and cyclophosphamide in a mouse model (Ding et al . 2002 ) . It would be interesting to learn if this synergism can be exploited in a clinical setting.
No placebo arm was included in this trial because it is already well established that STs for untreated HSA are poor. Because initial data on thalidomide suggested that a beneficial response was likely, the authors decided that they could not deny patients a potentially positive treatment, although identification of a beneficial effect must depend on blinded randomised trials. Furthermore, thalidomide is an expensive drug, with considerable legal and ethical issues surrounding its accessibility. We reasoned that a significant improvement in patient ST would need to be demonstrated to justify continued interest in this drug (or its analogues) as an adjuvant treatment for HSA. When compared to all previous historical studies, the results for thalidomide appear favourable (Table 3 ). In previous studies in which no adjuvant therapy was used, survival beyond 1 year may be observed in less than 10% of dogs (Wood et al . 1998 , Clifford et al . 2000 ). In the current study, five of the dogs receiving thalidomide -equating to one-third of the study population -survived more than 1 year after surgery. Even so, there are many problems in comparing results from one retrospective trial with those from another because of the difficulties in ensuring comparability of inclusion and exclusion criteria etc . Nevertheless, we consider the results of this study to provide sufficient evidence to support a prospective controlled study comparing thalidomide alongside other proven adjuvant agents. In conclusion, thalidomide appears to be well tolerated clinically and may improve survival for dogs following surgery for splenic HSA, especially for those with early stage disease.
